Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Engineering of Lurasidone Hydrochloride Loaded Niosomes for Enhancing the Antipsychotic Potential for Nasal Administration

Author(s): Sumit Sharma, Jai Bharti Sharma, Manish Kumar, Ravinder Verma, Deepak Kaushik and Shailendra Bhatt*

Volume 13, Issue 1, 2023

Published on: 07 February, 2023

Page: [39 - 55] Pages: 17

DOI: 10.2174/2468187313666230117163425

Price: $65

Abstract

Background: Drugs having high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc.

Objective: The present study aimed to develop Lurasidone loaded niosomes for nasal delivery.

Methods: Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation.

Results: The findings showed that the optimized formulation exhibited a particle size of 159.02 ± 0.58 nm and an entrapment efficiency of 91.6 ± 1.6%. The findings from the nasal histopathological analysis revealed that the optimized formulation was non-irritant and non-toxic for nasal mucosa. The findings from in vitro studies revealed 94.61 ± 0.27% of drug release from optimized formulation F7 throughout 24 hrs. The findings of in vivo (Albino Wistar rats) studies demonstrated that various pharmacokinetic parameters (Cmax, Tmax, AUC(0-24), T1/2, Vd and Cl) and pharmcodynamic parameters (conditioned avoidance response, biochemical estimation using oxidative markers such as superoxide dismutase, malondialdehyde and glutathione) were significantly improved compared to marketed tablets (Lurasid® 40 mg) and pure drug suspension. Optimized formulation F-7 exhibited 4.9 times more bioavailability than that of pure drug suspension following intranasal administration.

Conclusion: These findings indicate that nasal niosomal formulation of Lurasidone HCl is a promising nanoplatform for enhancing the overall performance of Lurasidone. These results could open new avenues into the future of nanomedicine.

Keywords: Lurasidone, niosomes, nasal administration, central composite design, nanotechnology, conditioned avoidance response.

« Previous Next »
Graphical Abstract

[1]
Nasal drug delivery market by dosage form, system, therapeutic applications, End user (Hospital, Homecare). Global forecast to 2021. Available from: https://www.marketsandmarkets.com/Market-Reports/nasal-drug-delivery-technology-market-192818058.html
[2]
Touitou E, Illum L. Nasal drug delivery. Drug Deliv Transl Res 2013; 3(1): 1-3.
[http://dx.doi.org/10.1007/s13346-012-0111-1] [PMID: 25787862]
[3]
Verma R, Kaushik A, Almeer R, et al. Improved pharmacodynamic potential of rosuvastatin by self-nanoemulsifying drug delivery system: An in vitro and in vivo evaluation. Int J Nanomedicine 2021; 16: 905-24.
[http://dx.doi.org/10.2147/IJN.S287665]
[4]
Mamidi N, Delgadillo RMV. Design, fabrication and drug release potential of dual stimuli-responsive composite hydrogel nanoparticle interfaces. Colloids Surf B Biointerfaces 2021; 204: 111819.
[http://dx.doi.org/10.1016/j.colsurfb.2021.111819] [PMID: 33964528]
[5]
Ge X, Wei M, He S, Yuan WE. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics 2019; 11(2): 55.
[http://dx.doi.org/10.3390/pharmaceutics11020055] [PMID: 30700021]
[6]
Belmaker RH. Lurasidone and bipolar disorder. Am J Psychiatry 2014; 171(2): 131-3.
[http://dx.doi.org/10.1176/appi.ajp.2013.13091240] [PMID: 24170243]
[7]
Kane JM. Lurasidone. J Clin Psychiatry 2011; 72 (Suppl. 1): 24-8.
[http://dx.doi.org/10.4088/JCP.10075su1.05] [PMID: 22217440]
[8]
Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011; 168(9): 957-67.
[http://dx.doi.org/10.1176/appi.ajp.2011.10060907] [PMID: 21676992]
[9]
Verma R, Mittal V, Kaushik D. Quality based design approach for improving oral bioavailability of valsartan loaded SMEDDS and study impact of lipolysis on the drug diffusion. Drug Deliv Lett 2018; 8(2): 130-9.
[http://dx.doi.org/10.2174/2210303108666180313141956]
[10]
Rasul A, Imran Khan M, Rehman M, et al. In vitro characterization and release studies of combined nonionic surfactant-based vesicles for the prolonged delivery of an immunosuppressant model drug. Int J Nanomedicine 2020; 15: 7937-49.
[http://dx.doi.org/10.2147/IJN.S268846] [PMID: 33116510]
[11]
Mamidi N, Velasco Delgadillo RM, Barrera EV, Ramakrishna S, Annabi N. Carbonaceous nanomaterials incorporated biomaterials: The present and future of the flourishing field. Compos, Part B Eng 2022; 243: 110150.
[http://dx.doi.org/10.1016/j.compositesb.2022.110150]
[12]
Rana SS, Bhatt S, Kumar M, et al. Design and optimization of itraconazole loaded sln for intranasal administration using central composite design. Nanosci Nanotechnol Asia 2020; 10(6): 884-91.
[http://dx.doi.org/10.2174/2210681209666191111113112]
[13]
Ruckmani K, Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech 2010; 11(3): 1119-27.
[http://dx.doi.org/10.1208/s12249-010-9480-2] [PMID: 20635228]
[14]
Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. AAPS PharmSciTech 2012; 13(3): 826-35.
[http://dx.doi.org/10.1208/s12249-012-9805-4] [PMID: 22644706]
[15]
Shilakari Asthana G, Sharma PK, Asthana A. In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica (Cairo) 2016; 2016: 1-10.
[http://dx.doi.org/10.1155/2016/6492953] [PMID: 27293976]
[16]
Veldurthi R, Abbaraju K. Formulation and evaluation of Etoricoxib niosomes by thin film hydration technique and ether ejection method. Nano Biomed Eng 2017; 9(3): 242-8.
[17]
Aggarwal G, Chandel P, Harikumar SL, Bansal S. Design and development of cefdinir niosomes for oral delivery. J Pharm Bioallied Sci 2013; 5(4): 318-25.
[http://dx.doi.org/10.4103/0975-7406.120080] [PMID: 24302841]
[18]
Mohanty D, Rani MJ, Haque MA, et al. Preparation and evaluation of transdermal naproxen niosomes: Formulation optimization to pre-clinical anti-inflammatory assessment on murine model. J Liposome Res 2020; 30(4): 377-87.
[http://dx.doi.org/10.1080/08982104.2019.1652646] [PMID: 31412744]
[19]
Ayesa U, Chong PLG. Polar lipid fraction E from Sulfolobus acidocaldarius and dipalmitoylphosphatidylcholine can form stable yet thermo-sensitive tetraether/diester hybrid archaeosomes with controlled release capability. Int J Mol Sci 2020; 21(21): 8388.
[http://dx.doi.org/10.3390/ijms21218388] [PMID: 33182284]
[20]
Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development and in vitro/in vivo evaluation of controlled release provesicles of a nateglinide–maltodextrin complex. Acta Pharm Sin B 2014; 4(5): 408-16.
[http://dx.doi.org/10.1016/j.apsb.2014.08.001] [PMID: 26579411]
[21]
Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 2011; 7(12): 4169-76.
[http://dx.doi.org/10.1016/j.actbio.2011.07.025] [PMID: 21839863]
[22]
Della Pelle G, Delgado López A, et al. Cyanine dyes for photo-thermal therapy: A comparison of synthetic liposomes and natural erythrocyte-based carriers. Int J Mol Sci 2021; 22(13): 6914.
[http://dx.doi.org/10.3390/ijms22136914]
[23]
Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm 2015; 41(12): 1968-77.
[http://dx.doi.org/10.3109/03639045.2015.1024685] [PMID: 25830370]
[24]
Swalve N, Mulholland MM, Li M. Alterations of acoustic features of 50 kHz vocalizations by nicotine and phencyclidine in rats. Behav Pharmacol 2019; 30(5): 446-51.
[http://dx.doi.org/10.1097/FBP.0000000000000463] [PMID: 30801260]
[25]
Patel MH, Mundada VP, Sawant KK. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: Optimization, In vitro characterization, cell line studies and in vivo efficacy in schizophrenia. Drug Dev Ind Pharm 2019; 45(8): 1242-57.
[http://dx.doi.org/10.1080/03639045.2019.1593434] [PMID: 30880488]
[26]
Tayyab Imtiaz M, Anwar F, Saleem U, et al. Triazine derivative as putative candidate for the reduction of hormone-positive breast tumor: In silico, pharmacological, and toxicological approach. Front Pharmacol 2021; 12: 686614.
[http://dx.doi.org/10.3389/fphar.2021.686614] [PMID: 34122114]
[27]
Asdaq SMB, Challa O, Alamri AS, et al. Cytoprotective potential of Aged Garlic Extract (AGE) and its active constituent, S-allyl-l-cysteine, in presence of carvedilol during isoproterenol-induced myocardial disturbance and metabolic derangements in rats. Molecules 2021; 26(11): 3203.
[http://dx.doi.org/10.3390/molecules26113203] [PMID: 34071846]
[28]
Bedir F, Kocatürk H, Yapanoğlu T, et al. Protective effect of taxifolin against prooxidant and proinflammatory kidney damage associated with acrylamide in rats. Biomed Pharmacother 2021; 139: 111660.
[http://dx.doi.org/10.1016/j.biopha.2021.111660] [PMID: 34243628]
[29]
Liu MJ, Guo HY, Liu B, et al. Gill oxidative damage caused by acute ammonia stress was reduced through the HIF-1α/NF-κb signaling pathway in golden pompano (Trachinotus ovatus). Ecotoxicol Environ Saf 2021; 222: 112504.
[http://dx.doi.org/10.1016/j.ecoenv.2021.112504] [PMID: 34265533]
[30]
Verma R, Kaushik D. Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential. Drug Deliv 2020; 27(1): 756-71.
[http://dx.doi.org/10.1080/10717544.2020.1760961] [PMID: 32397771]
[31]
Bnyan R, Khan I, Ehtezazi T, et al. Surfactant effects on lipid-based vesicle properties. J Pharm Sci 2018; 107(5): 1237-46.
[http://dx.doi.org/10.1016/j.xphs.2018.01.005] [PMID: 29336980]
[32]
Jeong IJ, Kim KJ. An interactive desirability function method to multiresponse optimization. Eur J Oper Res 2009; 195(2): 412-26.
[http://dx.doi.org/10.1016/j.ejor.2008.02.018]
[33]
Shaker S, Gardouh A, Ghorab M. Factors affecting liposomes particle size prepared by ethanol injection method. Res Pharm Sci 2017; 12(5): 346-52.
[http://dx.doi.org/10.4103/1735-5362.213979] [PMID: 28974972]
[34]
Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): Present state of development and industrial applications. Curr Drug Discov Technol 2011; 8(3): 207-27.
[http://dx.doi.org/10.2174/157016311796799062] [PMID: 21291409]
[35]
Arzani G, Haeri A, Daeihamed M, Bakhtiari-Kaboutaraki H, Dadashzadeh S. Niosomal carriers enhance oral bioavailability of carvedilol: Effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine 2015; 10: 4797-813.
[PMID: 26251598]
[36]
Shah P, Goodyear B, Haq A, Puri V, Michniak-Kohn B. Evaluation of quality by design elements impact for developing niosomes as promising topical drug delivery platform. Pharmaceutics 2020; 12(3): 246.
[http://dx.doi.org/10.3390/pharmaceutics12030246] [PMID: 32182792]
[37]
Champion JA, Katare YK, Mitragotri S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007; 121(1-2): 3-9.
[http://dx.doi.org/10.1016/j.jconrel.2007.03.022] [PMID: 17544538]

Rights & Permissions Print Cite
Article Metrics
16
7
© 2024 Bentham Science Publishers | Privacy Policy